Use your antibodies-online credentials, if available.
May have a role in the regulation of spermatogenesis.. 再加上，我们可以发PD-1 蛋白 (96) 和 PD-1 试剂盒 (27)和数多这个蛋白质的别的产品。
Showing 10 out of 731 products:
Human Polyclonal PD-1 Primary Antibody for BR, CyTOF - ABIN5012979
Wan, Nie, Liu, Feng, He, Xu, Zhang, Dong, Zhang: Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. in Journal of immunology (Baltimore, Md. : 1950) 2007
Show all 11 Pubmed References
Human Polyclonal PD-1 Primary Antibody for ELISA (Detection), FACS - ABIN4899871
Sakthivel, Ramanujam, Wang, Pirskanen, Lefvert: Programmed Death-1: from gene to protein in autoimmune human myasthenia gravis. in Journal of neuroimmunology 2008
Show all 9 Pubmed References
Human Monoclonal PD-1 Primary Antibody for BR, FACS - ABIN2689142
Bennett, Luxenberg, Ling, Wang, Marquette, Lowe, Khan, Veldman, Jacobs, Valge-Archer, Collins, Carreno: Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. in Journal of immunology (Baltimore, Md. : 1950) 2003
Show all 8 Pubmed References
Mouse (Murine) Monoclonal PD-1 Primary Antibody for BR, FACS - ABIN2689141
Nishimura, Agata, Kawasaki, Sato, Imamura, Minato, Yagita, Nakano, Honjo: Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. in International immunology 1997
Show all 7 Pubmed References
Human Polyclonal PD-1 Primary Antibody for IHC, ELISA - ABIN1002980
Holling, Schooten, van Den Elsen: Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. in Human immunology 2004
Show all 4 Pubmed References
Human Polyclonal PD-1 Primary Antibody for IHC, ELISA - ABIN1002981
Ishida, Agata, Shibahara, Honjo: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. in The EMBO journal 1992
Show all 4 Pubmed References
Human Monoclonal PD-1 Primary Antibody for ICC, FACS - ABIN438813
Dorrell, Abraham, Lanxon-Cookson, Canaday, Streeter, Grompe: Isolation of major pancreatic cell types and long-term culture-initiating cells using novel human surface markers. in Stem cell research 2009
Show all 3 Pubmed References
Mouse (Murine) Polyclonal PD-1 Primary Antibody for CyTOF, FACS - ABIN4899873
Kasagi, Kawano, Okazaki, Honjo, Morinobu, Hatachi, Shimatani, Tanaka, Minato, Kumagai: Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice. in Journal of immunology (Baltimore, Md. : 1950) 2010
Show all 3 Pubmed References
Human Polyclonal PD-1 Primary Antibody for IF (p), IHC (p) - ABIN735608
Zhang, Niyazi, Hong, Tuluwengjiang, Zhang, Zhang, Su, Bao: Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway. in Tumour biology 2017
Show all 2 Pubmed References
Human Monoclonal PD-1 Primary Antibody for FACS - ABIN2479653
Ochonisky, Chosidow, Kuentz, Man, Fraitag, Pelisse, Revuz: Cogan's syndrome. An unusual etiology of urticarial vasculitis. in Dermatologica 1992
Show all 3 Pubmed References
Alteration of the PD-1/PD-L1 (显示 CD274 抗体) pathway can modulate Treg/Th17 balance in asthmatic children.
The expression of PD1 on T cells was elevated in patients with rheumatoid arthritis and was correlated with the disease activity.
High expression of programmed death-1 in sentinel lymph nodes is associated with breast cancer.
We describe three cases of patients with mRCC treated with anti-PD-1 antibody therapy in combination with targeted therapy (bevacizumab), anti-cytotoxic T lymphocyte antigen 4 (显示 CTLA4 抗体) therapy (ipilimumab), or radiotherapy.
anti-CTLA4 (显示 CTLA4 抗体)/anti-PD-1/PD-L1 (显示 CD274 抗体) combinations versus anti-PD-1/PD-L1 (显示 CD274 抗体) monotherapy was selected as a factor independent of TMB (显示 MRPL55 抗体) for predicting better RR (77% vs. 21%; P = 0.004) and PFS (P = 0.024). Higher TMB (显示 MRPL55 抗体) predicts favorable outcome to PD-1/PD-L1 (显示 CD274 抗体) blockade across diverse tumors.
The altered soluble (s)PD1 and sICOS serum levels in the different Hepatitis b (HBV) groups may reflect the dysregulation of T cell activation, and may be associated with the HBV pathological process.
We found that PD-L1 (显示 CD274 抗体) expression was upregulated following TGF-beta (显示 TGFB1 抗体) induction; in contrast, it was downregulated by TGF-beta (显示 TGFB1 抗体) receptor-kinase inhibitors and the MET process. Furthermore, chemo-treatment increased TGF-beta (显示 TGFB1 抗体) expression and enhances PD-L1 (显示 CD274 抗体) expression via autocrine TGF-beta (显示 TGFB1 抗体) induced EMT (显示 ITK 抗体). Analysis of clinical samples revealed a significant relationship between PD-L1 (显示 CD274 抗体) expression and EMT (显示 ITK 抗体) status
this study demonstrated that PD-1 may involve in lymph nodes metastasis and promote the understanding of the mechanism of immunotherapies in the non-small cell lung cancer
PD-L1 (显示 CD274 抗体) expression in melanoma tumor cells is lower than NSCLC or renal cell carcinoma (显示 MOK 抗体) cells. The higher response rate in melanoma patients treated with PD-1 inhibitors is likely related to PD-L1 (显示 CD274 抗体) in tumor-associated inflammatory cells. Further studies are warranted to validate the predictive role of inflammatory cell PD-L1 (显示 CD274 抗体) expression in melanoma and determine its biological significance
Higher PRE PD-1(+) T cells in responders suggest active suppression of an engaged immune system that is disinhibited by anti-PD-1 therapies. Furthermore, immunoprofiling of EDT biopsies for increased PD-L1 (显示 CD274 抗体) expression and immune cell infiltration showed greater predictive utility than PRE biopsies and may allow better selection of patients most likely to benefit from anti-PD-1 therapies and warrants further evaluation
these data show that PD-1 expression is an intrinsic property of brain-resident memory CD8 (显示 CD8A 抗体) T cells in a persistent CNS viral infection
Our results demonstrate that entinostat enhances the antitumor effect of PD-1 targeting through functional inhibition of MDSCs and a transition away from an immune-suppressive tumor microenvironment. These data provide a mechanistic rationale for the clinical testing and potential markers of response of this novel combination in solid tumor patients.
synergism in cell death by Caspase-1 (显示 CASP1 抗体)- and RipK3 (显示 RIPK3 抗体) resulted in restriction of PD-1 and TIM3 (显示 HAVCR2 抗体) expression on primed CD8 (显示 CD8A 抗体)(+) T cells, which promoted the survival of activated CD8 (显示 CD8A 抗体)(+) T cells.
Tim-3 (显示 HAVCR2 抗体) and PD-1 pathways play critical roles in regulating CD8 (显示 CD8A 抗体)(+) T cell function and maintaining normal pregnancy.
Anti-PD-1/PD-L1 (显示 CD274 抗体) therapy inhibited CMT167 orthotopic lung tumors by 95%. .Silencing PD-L1 (显示 CD274 抗体) expression in CMT167 cells resulted in smaller orthotopic tumors that remained sensitive to anti-PD-L1 (显示 CD274 抗体) therapy, whereas implantation of CMT167 cells into PD-L1 (显示 CD274 抗体)(-) mice blocked orthotopic tumor growth, indicating a role for PD-L1 (显示 CD274 抗体) in both the cancer cell and the microenvironment.
Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1 (显示 CD274 抗体)) together with immune stimulatory agonist Abs like anti-OX40 (显示 TNFRSF4 抗体) are being tested in the clinic to achieve improved antitumor effects
Inhibition of Fut8 (显示 FUT8 抗体), a core fucosyltransferase, by genetic ablation or pharmacologic inhibition reduced cell-surface expression of PD-1 and enhanced T cell activation, leading to more efficient tumor eradication.
An examination of the mechanisms of immunity behind this long-term protection in PD-1 knockout mice showed a key role for parasite-specific CD8 (显示 CD8A 抗体)(+) T cells even when CD4 (显示 CD4 抗体)(+) T cells and B cells responded to re-infection.
To test the in vivo activity of REGN2810, which does not cross-react with murine PD-1, knock-in mice were generated to express a hybrid protein containing the extracellular domain of human PD-1, and transmembrane and intracellular domains of mouse PD-1
The combination of tumor vaccination to induce high avidity tumor specific T cell responses and PD-1 blockade synergises to provide tumor therapy and 85% survival in the aggressive B16 melanoma model.
Data show that CTLA-4 (显示 CTLA4 抗体)(+)PD-1(-) memory CD4 (显示 CD4 抗体)(+) T cells, which share phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood, lymph nodes (LN), spleen, and gut (显示 GUSB 抗体), and contained replication-competent and infectious virus.
Compared to before immunosuppression, PD-1 expression increased at reactivation. Increased T cells before zoster is likely due to virus reactivation.
A PD-1(high) phenotype is associated with accelerated in vivo CD8 (显示 CD8A 抗体) T cell turnover in SIV-infections, especially within the SIV-specific CD8 (显示 CD8A 抗体) T cell pool.
High levels of PD-1 expression on CD4 (显示 CD4 抗体)(+) T cells in lymph nodes of rhesus macaques can serve as a valuable marker to identify T follicular helper cells.
Data indicate that PD-1 expression is increased as a result of T cell activation during a primary immune response as well as during persistent immune activation in macaques.
PD-1 can serve as a sensitive indicator of persistent, low-level virus replication
This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases.
programmed cell death protein 1
, protein PD-1
, programmed cell death 1
, programmed death 1